Samsung Biologics Expands its Development Partnership with STCube for STM418

 Samsung Biologics Expands its Development Partnership with STCube for STM418

Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China

Shots:

  • Samsung Biologics to offer CDO services from cell line development, process development, non-clinical & clinical material manufacturing, to IND submission for global clinical trials of STM418
  • The companies have signed their second CDO agreement following the first signed CDO immunology partnership for STT-003 in Mar 2020. The focus of the agreement is to get IND approval further evaluating the candidate in global clinical trials to prove the enhanced efficacy vs existing PD-1 Abs
  • STM418 is a mAb that selectively masks glycosylation site N58 on PD-1 that inhibits PD-1/PD-L1 binding to enhance anti-tumor immunity

Click here to read full press release/ article | Ref: Samsung Biologics | Image: Twitter

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post